CervoMed (NASDAQ: CRVO) has recently received a number of price target changes and ratings updates: 12/17/2024 – CervoMed was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating. 12/11/2024 – CervoMed had its “underweight” rating reaffirmed by analysts at Morgan Stanley. 12/11/2024 – CervoMed had its “neutral” rating reaffirmed by [...]
Related news